Form 8-K - Current report:
SEC Accession No. 0001193125-25-139950
Filing Date
2025-06-12
Accepted
2025-06-12 16:24:43
Documents
12
Period of Report
2025-06-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d940498d8k.htm   iXBRL 8-K 27179
  Complete submission text file 0001193125-25-139950.txt   142207

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250610.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250610_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250610_pre.xml EX-101.PRE 11266
15 EXTRACTED XBRL INSTANCE DOCUMENT d940498d8k_htm.xml XML 3678
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 251043064
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)